441 related articles for article (PubMed ID: 27807948)
21. Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions: A Subanalysis of the International, Multicenter GHOST-EU Registry.
Geraci S; Kawamoto H; Caramanno G; Ruparelia N; Capodanno D; Brugaletta S; Gori T; Nef H; Sabate M; Mehilli J; Lesiak M; Naber C; Di Mario C; Capranzano P; Wiebe J; Araszkiewicz A; Pyxaras S; Mattesini A; Münzel T; Tamburino C; Colombo A; Latib A
JACC Cardiovasc Interv; 2017 Mar; 10(6):560-568. PubMed ID: 28259663
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease-AIDA trial substudy.
Tijssen RYG; van der Schaaf RJ; Kraak RP; Vink MA; Hofma SH; Arkenbout EK; Weevers APJD; Kerkmeijer LSM; Onuma Y; Serruys PW; Beijk MAM; Koch KT; Baan J; Vis MM; Piek JJ; Tijssen JGP; Henriques JPS; de Winter RJ; Wykrzykowska JJ
Catheter Cardiovasc Interv; 2020 Jan; 95(1):89-96. PubMed ID: 30968559
[TBL] [Abstract][Full Text] [Related]
23. Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study).
Moscarella E; Tanaka A; Ielasi A; Cortese B; Coscarelli S; De Angelis MC; Piraino D; Latib A; Grigis G; Bianchi R; Buccheri D; Calabrò P; Tespili M; Silva Orrego P; Colombo A; Varricchio A
Catheter Cardiovasc Interv; 2018 Oct; 92(4):668-677. PubMed ID: 29356269
[TBL] [Abstract][Full Text] [Related]
24. 2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent.
Xu B; Saito Y; Baumbach A; Kelbæk H; van Royen N; Zheng M; Morel MA; Knaapen P; Slagboom T; Johnson TW; Vlachojannis G; Arkenbout KE; Holmvang L; Janssens L; Ochala A; Brugaletta S; Naber CK; Anderson R; Rittger H; Berti S; Barbato E; Toth GG; Maillard L; Valina C; Buszman P; Thiele H; Schächinger V; Lansky A; Wijns W;
JACC Cardiovasc Interv; 2019 Sep; 12(17):1679-1687. PubMed ID: 31129092
[TBL] [Abstract][Full Text] [Related]
25. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
Muramatsu T; Onuma Y; van Geuns RJ; Chevalier B; Patel TM; Seth A; Diletti R; García-García HM; Dorange CC; Veldhof S; Cheong WF; Ozaki Y; Whitbourn R; Bartorelli A; Stone GW; Abizaid A; Serruys PW; ; ; ; ; ;
JACC Cardiovasc Interv; 2014 May; 7(5):482-93. PubMed ID: 24746650
[TBL] [Abstract][Full Text] [Related]
26. A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy.
Jiménez VA; Iñiguez A; Baz JA; Valdés M; Ortiz A; Vuilliomenet A; Mainar V; Dudek D; Banai S; Tüller D; Bonnet JL; De Miguel A; Bastos G; Wijns W; Saito S
Cardiovasc Revasc Med; 2016 Sep; 17(6):355-61. PubMed ID: 27156201
[TBL] [Abstract][Full Text] [Related]
27. The Pt-Cr everolimus-eluting stent with bioabsorbable polymer in the treatment of patients with acute coronary syndromes. Results from the SYNERGY ACS registry.
de la Torre Hernandez JM; Moreno R; Gonzalo N; Rivera R; Linares JA; Veiga Fernandez G; Gomez Menchero A; Garcia Del Blanco B; Hernandez F; Benito Gonzalez T; Subinas A; Escaned J
Cardiovasc Revasc Med; 2019 Aug; 20(8):705-710. PubMed ID: 30414798
[TBL] [Abstract][Full Text] [Related]
28. Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial.
Kufner S; Byrne RA; Valeskini M; Schulz S; Ibrahim T; Hoppmann P; Schneider S; Laugwitz KL; Schunkert H; Kastrati A;
EuroIntervention; 2016 Mar; 11(12):1372-9. PubMed ID: 25405657
[TBL] [Abstract][Full Text] [Related]
29. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients With Diabetes Mellitus: Results of the Absorb Diabetic Substudy.
Kereiakes DJ; Ellis SG; Kimura T; Abizaid A; Zhao W; Veldhof S; Vu MT; Zhang Z; Onuma Y; Chevalier B; Serruys PW; Stone GW
JACC Cardiovasc Interv; 2017 Jan; 10(1):42-49. PubMed ID: 28017311
[TBL] [Abstract][Full Text] [Related]
31. Three-month evaluation of strut healing using a novel optical coherence tomography analytical method following bioresorbable polymer everolimus-eluting stent implantation in humans: the TIMELESS study.
Vesga B; Hernandez H; Moncada M; Gasior P; Higuera S; Dager A; Arana C; Delgado JA; Généreux P; Maehara A; Granada JF
Coron Artery Dis; 2017 Mar; 28(2):126-134. PubMed ID: 27879518
[TBL] [Abstract][Full Text] [Related]
32. Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent.
Meredith IT; Verheye S; Weissman NJ; Barragan P; Scott D; Valdés Chávarri M; West NE; Kelbæk H; Whitbourn R; Walters DL; Kubica J; Thuesen L; Masotti M; Banning A; Sjögren I; Stables RH; Allocco DJ; Dawkins KD
EuroIntervention; 2013 Jul; 9(3):308-15. PubMed ID: 23872647
[TBL] [Abstract][Full Text] [Related]
33. Comparison of neointimal coverage between durable-polymer everolimus-eluting stents and bioresorbable-polymer everolimus-eluting stents 1 year after implantation using high-resolution coronary angioscopy.
Nojima Y; Adachi H; Ihara M; Kurimoto T; Okayama K; Sakata Y; Nanto S
Catheter Cardiovasc Interv; 2019 Aug; 94(2):204-209. PubMed ID: 30737973
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes of overlapping versus non-overlapping everolimus-eluting absorb bioresorbable vascular scaffolds: An analysis from the multicentre prospective RAI registry (ClinicalTrials.gov identifier: NCT02298413).
Tarantini G; Mojoli M; Masiero G; Cortese B; Loi B; Varricchio A; Gabrielli G; Durante A; Pasquetto G; Calabrò P; Gistri R; Tumminello G; Misuraca L; Pisano F; Ielasi A; Mazzarotto P; Coscarelli S; Lucci V; Moretti L; Nicolino A; Colombo A; Olivari Z; Fineschi M; Piraino D; Piatti L; Canosi U; Tellaroli P; Corrado D; Rovera C; Steffenino G;
Catheter Cardiovasc Interv; 2018 Jan; 91(1):E1-E16. PubMed ID: 28500737
[TBL] [Abstract][Full Text] [Related]
35. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
[TBL] [Abstract][Full Text] [Related]
36. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
[TBL] [Abstract][Full Text] [Related]
37. Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent.
Dalos D; Gangl C; Roth C; Krenn L; Scherzer S; Vertesich M; Lang I; Maurer G; Neunteufl T; Berger R; Delle-Karth G
BMC Cardiovasc Disord; 2016 May; 16():104. PubMed ID: 27225486
[TBL] [Abstract][Full Text] [Related]
38. A prospective evaluation of a standardized strategy for the use of a polymeric everolimus-eluting bioresorbable scaffold in ST-segment elevation myocardial infarction: Rationale and design of the BVS STEMI STRATEGY-IT study.
Ielasi A; Varricchio A; Campo G; Leoncini M; Cortese B; Vicinelli P; Brugaletta S; di Uccio FS; Latib A; Tespili M
Catheter Cardiovasc Interv; 2017 Jun; 89(7):1129-1138. PubMed ID: 27774758
[TBL] [Abstract][Full Text] [Related]
39. Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the Treatment of Coronary Artery Disease: A Matched Comparison.
Wiebe J; Dörr O; Ilstad H; Husser O; Liebetrau C; Boeder N; Bauer T; Möllmann H; Kastrati A; Hamm CW; Nef HM
JACC Cardiovasc Interv; 2017 Mar; 10(5):477-485. PubMed ID: 28216214
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of the Absorb Bioresorbable Vascular Scaffold in Females and Males: Results of an Individual Patient-Level Pooled Meta-Analysis of Randomized Controlled Trials.
Shreenivas S; Kereiakes DJ; Ellis SG; Gao R; Kimura T; Onuma Y; Piard-Ruster K; Zhang Y; Koo K; Vu MT; Serruys PW; Stone GW
JACC Cardiovasc Interv; 2017 Sep; 10(18):1881-1890. PubMed ID: 28935081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
